• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure.

作者信息

Waaler A, Svaland M, Fauchald P, Jakobsen J A, Kolmannskog F, Berg K J

机构信息

Nycomed A.S., Research and Development Division, National Hospital, Oslo, Norway.

出版信息

Nephron. 1990;56(1):81-5. doi: 10.1159/000186105.

DOI:10.1159/000186105
PMID:2234253
Abstract

The dialyzability of iohexol was examined in patients with chronic renal failure on long-term hemodialysis treatment. Eight patients had iohexol (Omnipaque 240 or 350 mg I/ml) injected in doses between 98 and 1,493 mg I/kg body weight (BW) 25 h (mean time) before start of hemodialysis. Dialysance of iohexol was 81 +/- 15 ml/min (mean +/- SD) compared to 120 +/- 16.8 ml/min for creatinine. Elimination half-life for iohexol during hemodialysis was 3.9 +/- 1.1 h while plasma clearance was 64 +/- 17 ml/min. The distribution volume calculated (0.25 +/- 0.05 liters/kg BW) confirms previous observations with distribution in the extracellular fluid only. Before the start of hemodialysis 36 +/- 28% of the dose injected was eliminated, indicating some extrarenal elimination. After 4 h of hemodialysis 72 +/- 11% of the dose was removed.

摘要

相似文献

1
Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure.
Nephron. 1990;56(1):81-5. doi: 10.1159/000186105.
2
Assessing residual renal function and efficiency of hemodialysis--an application for urographic contrast media.评估残余肾功能及血液透析效率——尿路造影剂的一项应用
Nephron. 2000 Aug;85(4):324-33. doi: 10.1159/000045682.
3
Hemodialysis for elimination of the nonionic contrast medium iohexol after angiography in patients with impaired renal function.肾功能受损患者血管造影后采用血液透析清除非离子型造影剂碘海醇。
Nephron. 1995;70(4):430-7. doi: 10.1159/000188641.
4
Elimination of low-osmolality contrast media by hemodialysis.通过血液透析清除低渗造影剂。
Acta Radiol. 1996 Nov;37(6):966-71. doi: 10.1177/02841851960373P2104.
5
Elimination of the nonionic contrast medium iopromide in end-stage renal failure by hemodialysis.血液透析清除终末期肾衰竭患者体内的非离子型造影剂碘普罗胺。
Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd. 1989;128:119-23.
6
Elimination of non-ionic contrast medium by hemodialysis in patients with impaired renal function.肾功能受损患者通过血液透析清除非离子型造影剂。
Nihon Ika Daigaku Zasshi. 1999 Oct;66(5):305-7. doi: 10.1272/jnms.66.305.
7
Elimination of ioversol by hemodialysis.
Acta Radiol. 1996 Sep;37(5):826-9. doi: 10.1177/02841851960373P278.
8
Reduced iopromide elimination in hemodialysis with cuprophan membranes.
Acta Radiol. 2000 Nov;41(6):671-3. doi: 10.1080/028418500127346135.
9
Determination of residual renal function with iohexol clearance in hemodialysis patients.血液透析患者中用碘海醇清除率测定残余肾功能
Kidney Int. 1996 Jan;49(1):232-5. doi: 10.1038/ki.1996.32.
10
Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients.
Pharmacology. 1985;31(4):189-93. doi: 10.1159/000138114.

引用本文的文献

1
Meta-Analysis of Prophylactic Renal Replacement Therapy after Cardiac Catheterization in Patients with Chronic Kidney Disease.心脏导管插入术治疗慢性肾脏病患者的预防性肾脏替代治疗的荟萃分析。
Anatol J Cardiol. 2023 Sep 1;27(9):504-512. doi: 10.14744/AnatolJCardiol.2023.3443. Epub 2023 Aug 21.
2
Contrast volume and in-hospital outcomes of dialysis patients undergoing percutaneous coronary intervention.对比行经皮冠状动脉介入治疗的透析患者的对比剂用量和院内结局。
Sci Rep. 2022 Oct 21;12(1):17718. doi: 10.1038/s41598-022-21815-y.
3
Cholecystitis and Cholangitis during Continuous Renal Replacement Therapy in a Patient with Retroperitoneal Hemorrhage Requiring Large Amounts of Contrast Medium for the Assessment and Intervention.
一名腹膜后出血患者在连续肾脏替代治疗期间发生胆囊炎和胆管炎,该患者需要大量造影剂进行评估和干预。
Intern Med. 2022 Aug 15;61(16):2533-2537. doi: 10.2169/internalmedicine.8518-21. Epub 2022 Feb 1.
4
Contrast-associated acute kidney injury: does it really exist, and if so, what to do about it?对比剂相关急性肾损伤:它真的存在吗?如果存在,该如何应对?
F1000Res. 2019 May 29;8. doi: 10.12688/f1000research.16347.1. eCollection 2019.
5
Preventing contrast-induced nephropathy in patients with baseline renal dysfunction undergoing coronary angiography.
Curr Treat Options Cardiovasc Med. 2009 Feb;11(1):71-8. doi: 10.1007/s11936-009-0008-6.
6
Bench-to-bedside review: preventive measures for contrast-induced nephropathy in critically ill patients.从实验台到病床的综述:危重症患者对比剂肾病的预防措施
Crit Care. 2005 Aug;9(4):361-70. doi: 10.1186/cc3028. Epub 2005 Jan 7.